Table 1B.
Demographic and Baseline Characteristics (Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in Raltegravir and Ritonavir-Boosted Protease Inhibitor Groups)
| |
Raltegravir |
Ritonavir-boosted protease inhibitor |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Abacavir/lamivudine (n=27) | Tenofovir/emtricitabine (n=73) | p-value | Abacavir/lamivudine (n=27) | Tenofovir/emtricitabine (n=70) | p-value | |||||
| Age, years [median (IQR)] | 47 | (43–60) | 44 | (39–48) | 0.002 | 45 | (38–52) | 44 | (40–48) | 0.68 |
| Female sex [n (%)] | 3 | (11.11) | 17 | (23.29) | 0.26 | 7 | (25.93) | 20 | (28.57) | 1 |
| Ritonavir-boosted protease inhibitors at entry [n (%)] | ||||||||||
| Lopinavir/ritonavir | 11 | (40.74) | 35 | (47.95) | 14 | (51.85) | 33 | (47.14) | ||
| Atazanavir/ritonavir | 11 | (40.74) | 25 | (34.25) | 9 | (33.33) | 22 | (31.43) | ||
| Fosamprenavir/ritonavir | 5 | (18.52) | 7 | (9.59) | 4 | (14.81) | 7 | (10) | ||
| Saquinavir/ritonavir | — | (0) | 3 | (4.11) | — | (0) | 8 | (11.43) | ||
| Darunavir/ritonavir | — | (0) | 1 | (1.37) | ||||||
| Tipranavir/ritonavir | — | (0) | 1 | (1.37) | ||||||
| Patients on their first antiretroviral regimen [n (%)] | 4 | (14.81) | 10 | (13.7) | 1 | 5 | (18.52) | 8 | (11.43) | 0.50 |
| Exposure to antiretroviral therapy (years) [median (range)] | 10.65 | (5.02–12.73) | 9.22 | (2.7–12.33) | 0.39 | 8.17 | (3.81–10.89) | 10.73 | (4.44–13.15) | 0.05 |
| Exposure to protease inhibitor-based therapy (months) [median (range)] | 29.4 | (19.53–45.23) | 29.55 | (18.23–35.67) | 0.58 | 27.78 | (13–39.73) | 29.02 | (19–37.93) | 0.48 |
| Patients with previous suboptimal antiretroviral therapy [n (%)] | 11 | (40.74) | 26 | (35.62) | 0.64 | 4 | (14.81) | 29 | (41.43) | 0.01 |
| Patients with previous virological failure [n (%)] | 4 | (14.81) | 28 | (38.36) | 0.033 | 3 | (11.11) | 26 | (37.14) | 0.01 |
| Patients with previous suboptimal antiretroviral therapy or virological failure [n (%)] | 14 | (51.85) | 35 | (47.95) | 0.82 | 5 | (18.52) | 35 | (50) | <0.001 |
| Number of previous antiretroviral regimens [median (IQR)] | 5.5 | (2–9) | 4 | (2–6) | 0.22 | 4 | (2–4) | 5 | (3–8) | 0.04 |
| Number of previous suboptimal antiretroviral regimens [median (IQR)] | 2 | (1–3) | 2 | (1–3) | 0.76 | 1.5 | (1–2) | 2 | (1–3) | 0.31 |
| Number of previous virological failures [median (IQR)] | 1.5 | (1–2) | 1 | (1–3) | 0.73 | 2 | (1–4) | 1 | (1–2) | 0.48 |
| Patients with AIDS [n (%)] | 11 | (40.74) | 37 | (50.68) | 0.05 | 14 | (51.84) | 34 | (48.57) | 0.82 |
| CD4 cell count (cells/ml) [median (IQR)] | 565.5 | (416–806) | 477.4 | (348.14–731.4) | 0.23 | 467.04 | (350.4–735.05) | 501 | (384–685.1) | 0.76 |
| CD8 cell count (cells/ml) [median (IQR)] | 845.34 | (577.98–1275) | 832.8 | (680.95–1071.9) | 0.78 | 756 | (577.5–974.4) | 718.1 | (504–1071.33) | 0.558781 |
| Triglycerides (mg/dl) [median (IQR)] | 168.29 | (149.9–268) | 151.29 | (100.5–242.5) | 0.11 | 198 | (150.58–282) | 157 | (104–231.15) | 0.02 |
| Triglycerides >200 mg/dl [n (%)] | 10 | (37.04) | 25 | (34.25) | 0.81 | 13 | (48.15) | 23 | (32.86) | 0.17 |
| Total cholesterol (mg/dl) [median (IQR)] | 217.69 | (193–244) | 198 | (168.5–226.5) | 0.04 | 221 | (187–242) | 190.5 | (167.5–217.5) | <0.001 |
| Total cholesterol >240 mg/dl [n (%)] | 7 | (25.93) | 9 | (12.33) | 0.12 | 7 | (25.93) | 8 | (11.43) | 0.11 |
| LDL cholesterol (mg/dl) [median (IQR)] | 128.5 | (108.5–139) | 124 | (95.8–147) | 0.83 | 138.46 | (100–163) | 113 | (96.9–144) | 0.12 |
| LDL cholesterol >160 mg/dl [n (%)] | 9 | (33.33) | 28 | (38.36) | 0.81 | 6 | (22.22) | 27 | (38.57) | 0.15 |
| HDL cholesterol (mg/dl) [median (IQR)] | 45 | (38.85–58.85) | 44.7 | (33–54) | 0.19 | 49.81 | (41–56) | 41.62 | (34.25–49.35) | 0.01 |
| HDL cholesterol <40 mg/dl [n (%)] | 2 | (7.41) | 12 | (16.44) | 0.34 | 7 | (25.93) | 4 | (5.71) | <0.001 |
| Lipid-lowering therapy at entry [n (%)] | 5 | (18.52) | 8 | (10.96) | 0.32 | 9 | (33.33) | 11 | (15.71) | 0.09 |